Prostate Cancer Foundation’s goal is always to deliver the most cutting-edge treatments and information to families dealing with prostate cancer. As such, they have committed to updating the patient guide to reflect the very latest research and discoveries for patients.
This is our third round of updates for 2019. Changes include:
- Updated information on local treatments for recurrent prostate cancer
- Updated information on therapies for metastatic hormone-sensitive prostate cancer
- New FDA approval of darolutamide for non-metastatic CRPC
- New information about non-hormonal therapy options for select patients
- New information on the use of PARP inhibitors as an emerging therapy
- Updated recommendations on when to talk to your doctor about PSA screening
- Updated nutrition recommendations
Download an updated digital copy today and then be sure to provide feedback.
URO Today has published a collection of videos from the APCC 2019 conference. This informative collection of 60 short videos cover a wide range of prostate cancer topics. You can view the video collection on URO Today HERE
Don’t get confused with all the various prostate cancer terms and drugs. The following resources can help you with these. You can also find these links in the Resources section of this website.
PCF has updated it’s 2019 Patient Guide. Compiled with the contributions of top-tier doctors and researchers in prostate cancer, it is a must-have resource for patients and families. It focuses all of the information available about contemporary prostate cancer research, treatment, and lifestyle factors into one consolidated document.
Get it HERE.
As many as 40% of newly diagnosed PCa patients have unifocal disease, that is, just one focus of cancer. But that still leaves 60-80% of patients with multifocal PCa. Without evidence to the contrary, multiple foci in the same gland were thought to be biologically homogeneous, that is, identical to each other.
Then, along came the tools to analyze PCa at the molecular level, bringing new knowledge of the biology of PCa.
Read about this by clicking here.
If you experience a frequent urge to urinate—perhaps due to having an enlarged prostate if you’re a man, having given birth if you’re a woman, or having an “overactive bladder”—there may be a practical do-it-yourself solution to the problem, referred to as bladder training. It’s worth a try before resorting to medication or surgical procedures.
Read more at berkeleywellness.com HERE
So you’ve had your PSA test, and it came back high. Your doctor did a DRE and ran a few more tests, and assures you that prostate cancer is very unlikely. Still, you’re worried. What are some other causes of a high PSA?
Read about this in the Prostate Care Foundation blog HERE
UC San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer. Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments in mice and with human cells showed that blocking this stress response with an experimental drug—previously shown to enhance cognition and restore memory after brain damage in rodents—causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.
The new study was published online May 2, 2018 in Science Translational Medicine.
Read the entire article on MedicalXpress.com HERE
and technologyneworks.com HERE
The American Urological Association (AUA) has just issued a complete set of new guidelines by Mulhall et al. entitled “Evaluation and management of testosterone deficiency: AUA guideline” which includes specific guidance about the appropriateness of testosterone supplements in men diagnosed with prostate cancer.
Read the article on The Prostate Cancer Infolink here
Read the PCRI Spring 2018 Prostate Digest here